Table 2.
Treatment satisfaction: shift from baseline to week 8 in the modified intent-to-treat population (n = 382)
| Variable | Baseline satisfaction with adalimumab (week -2)/etanercept (week -1) | ||||
|---|---|---|---|---|---|
| Very dissatisfied | Somewhat dissatisfied | Neither satisfied nor dissatisfied | Somewhat satisfied | Very satisfied | |
| Satisfaction with injection frequency at week 8 | |||||
| Na | 22 | 58 | 109 | 94 | 100 |
| Very dissatisfied | 1 (4.5) | 5 (8.6) | 5 (4.6) | 4 (4.3) | 8 (8.0) |
| Somewhat dissatisfied | 0 | 2 (3.4) | 8 (7.3) | 5 (5.3) | 4 (4.0) |
| Neither satisfied nor dissatisfied | 2 (9.1) | 5 (8.6) | 11 (10.1) | 10 (10.6) | 4 (4.0) |
| Somewhat satisfied | 2 (9.1) | 8 (13.8) | 21 (19.3) | 14 (14.9) | 13 (13.0) |
| Very satisfied | 17 (77.3) | 38 (65.5) | 64 (58.7) | 61 (64.9) | 71 (71.0) |
| Satisfaction with the injectable device at week 8 | |||||
| Na | 30 | 30 | 62 | 102 | 158 |
| Very dissatisfied | 3 (10.0) | 4 (13.3) | 3 (4.8) | 5 (4.9) | 10 (6.3) |
| Somewhat dissatisfied | 3 (10.0) | 0 | 4 (6.5) | 8 (7.8) | 10 (6.3) |
| Neither satisfied nor dissatisfied | 1 (3.3) | 1 (3.3) | 8 (12.9) | 6 (5.9) | 13 (8.2) |
| Somewhat satisfied | 6 (20.0) | 4 (13.3) | 14 (22.6) | 21 (20.6) | 17 (10.8) |
| Very satisfied | 17 (56.7) | 21 (70.0) | 33 (53.2) | 62 (60.8) | 108 (68.4) |
| Overall satisfaction with injection experience at week 8 | |||||
| Na | 19 | 35 | 86 | 119 | 123 |
| Very dissatisfied | 0 | 6 (17.1) | 5 (5.8) | 5 (4.2) | 8 (6.5) |
| Somewhat dissatisfied | 0 | 0 | 1 (1.2) | 3 (2.5) | 2 (1.6) |
| Neither satisfied nor dissatisfied | 1 (5.3) | 3 (8.6) | 12 (14.0) | 5 (4.2) | 9 (7.3) |
| Somewhat satisfied | 3 (15.8) | 5 (14.3) | 22 (25.6) | 25 (21.0) | 20 (16.3) |
| Very satisfied | 15 (78.9) | 21 (60.0) | 46 (53.5) | 81 (68.1) | 84 (68.3) |
Data are presented as N (%) unless otherwise indicated
aIncludes only patients who had provided the answer at both baseline and week 8 for a given question